Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Researchers discover mechanism that explains how chromosomal translocations are not random

Researchers at the UC San Diego School of Medicine have pinpointed a mechanism that may help explain how chromosomal translocations - the supposedly random shuffling of large chunks of DNA that frequently lead to cancer - aren't so random after all. They have developed a model of such chromosomal mix-ups in prostate cancer which indicates that the male sex hormone (androgen) receptor unexpectedly plays a key role in driving specific translocations in the development of cancer.

4 Dec 2009

Pfizer announces a $9M cancer research collaboration in British Columbia

Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.

4 Dec 2009

KFDA approves RPC's Onko-Sure in Vitro Diagnostic cancer test

US-based pharmaceutical company Radient Pharmaceuticals Corporation (RPC) announced today the Korean Food & Drug Administration (KFDA) has approved RPC's Onko-Sure™ in Vitro Diagnostic cancer test for routine clinical testing and government reimbursement throughout Korea.

4 Dec 2009

Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its extended-duration testosterone undecanoate injection, AVEED(TM), for men diagnosed with low testosterone.

3 Dec 2009

IsoRay to distribute Oncura's I-125 brachytherapy seed

IsoRay, Inc. announced today that it has signed a distribution agreement with Oncura to distribute the I-125 brachytherapy seed, OncoSeed™.

3 Dec 2009

Continued rise of PSA value in prostate cancer patients can indicate relapsing disease

Prostate cancer patients who have a prostate-specific antigen (PSA) value of less than or equal to 1.5 at two years after external beam radiation therapy (EBRT) are less likely to have a cancer recurrence and cancer-related death, according to a study in the December 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

3 Dec 2009

Macular Health eye vitamin supplement improves visual acuity

Adults are more likely to lose their vision than be diagnosed with cancer. For adults 65 and over, the odds of losing vision are one in three, whereas the odds of a man developing prostate cancer are one in six and odds of a woman developing breast cancer are one in nine. Vision loss threatens the overall health of aging adults by increasing the risk of injuries, depression and inability to complete daily tasks.

3 Dec 2009

Breast Cancer Fund: Congress must enforce BPA ban in food and beverage containers

In the wake of the first evidence that American babies are born contaminated with a plastics chemical linked to birth defects and breast cancer, Congress must act immediately to protect infants and mothers.

3 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Cancer Prevention Research Conference highlights new research on cancer

The American Association for Cancer Research Frontiers in Cancer Prevention Research Conference will focus on the latest biological, medical and social research behind cancer prevention.

2 Dec 2009

Boehringer Ingelheim to announce positive results from its RE-COVER study

Boehringer Ingelheim will announce positive results from the landmark RE-COVER™ study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009. The RE-COVER™ study assessed dabigatran etexilate in a head-to-head comparison with the current standard in care, warfarin, for the treatment of acute venous thromboembolism (VTE), enabling healthcare professionals to make direct comparisons and care based value judgements.

2 Dec 2009

RapidArc radiotherapy technology delivers highly-precise IMRT treatment

Former New Jersey Assemblyman Francis Bodine was surprised and delighted when his radiotherapy treatment sessions for prostate cancer went from about 20 minutes each day to less than five.

2 Dec 2009

New figures show steady decline in European cancer deaths, but variations exist between gender and countries

New figures show there was a steady decline in cancer deaths in the European Union between 1990-1994 and 2000-2004.

1 Dec 2009

Majority of Canadians join global charity event to raise awareness on prostate cancer

Movember, the month formerly known as November, is proud to share that 35,068 Canadians across the country joined the movement by growing a Mo (slang for moustache) and supporting men's health issues. This year over $6.3 million has been raised for Prostate Cancer Canada, with funds continuing to pour in.

1 Dec 2009

MAbs for early detection of cancer

Two sets of recommendations issued earlier this month have revised longstanding guidelines concerning the age at which women should first be tested for breast and cervical cancer and how frequently.

1 Dec 2009

Third-quarter fiscal 2009 results announced by Urodynamix Technologies

Urodynamix Technologies Ltd. today reported its financial results for its fiscal third quarter ended September 30, 2009. The Company reported a loss of $638,287 or $0.01 per share basic and diluted compared to a loss of $737,341or $0.01, basic and diluted, for the comparative quarter of the prior year. Revenue for the quarter ended September 30, 2009 at $15,285, decreased 55% over the same quarter of the prior year.

1 Dec 2009

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R).

30 Nov 2009

Sentinelle Medical, Siemens Healthcare to jointly develop solutions for Interventional Prostate MRI

Sentinelle Medical Inc., a leading manufacturer of breast MRI coils and software, and Siemens Healthcare today announced at the Radiological Society of North America (RSNA) annual meeting in Chicago, that they are collaborating on the development of a suite of innovative solutions for Interventional Prostate MRI.

30 Nov 2009

Study on deaths from cancer in Europe shows steady decline in mortality

New figures on deaths from cancer in Europe show a steady decline in mortality between the periods 1990-1994 and 2000-2004. Deaths from all cancers in the European Union (EU) between these two periods fell by nine percent in men and eight percent in women, with a large drop among the middle-aged population.

29 Nov 2009

Emerging cancer vaccines: Forecasts, new developments and pipeline analysis

The H1N1 vaccine has spurred media interest in vaccines, as well as predictions of vaccines for a host of new diseases. According to Kalorama Information, certain cancers may be added to the list of diseases for which vaccinations will be employed.

25 Nov 2009